Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis

British Journal of Dermatology

Volumn 150, Issue 1, 2004, Pages 132-135

  Dauden E ^a   Sanchez Peinado C ^b   Ruiz Genao, D ^a   Garcia F Villalta M ^a   Onate, M J ^c   Garcia Diez A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Centro de Especialidades de Fuencarral   (Spain)

Author keywords

Mycophenolate mofetil; Mycophenolic acid; Psoriasis

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LABORATORY TEST; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; REMISSION;

ADULT; AGED; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT COMPLIANCE; PRODRUGS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1242320217     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05563.x     Document Type: Article

References (9)

1. Geilen CC, Tebbe B, García-Bartels C et al. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-2.
2. Haufs MG, Beissert S, Grabbe S et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-81.
3. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999; 40: 135-7.
4. Nousari HC, Sragovich A, Kimyai-Asadi A et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-8.
5. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-7.
6. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001; 144: 583-6.
7. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil In severe psoriasis. Br J Dermatol 2000; 143: 405-7.
8. Bullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315-24.
9. Mariette V, Güntert W, Gernott S et al. Evaluation of the EMIT mycophenolic acid assay from Dade Behring. Ther Drug Monit 1999; 21: 638-43.